Compare Johnson & Johnson (JNJ) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Banco Santander SA — how do they compare? Johnson & Johnson trades at $250.09 (market cap $598.96B), while Banco Santander SA trades at $13.52 (market cap $191.46B). The key difference: Johnson & Johnson is far larger — about 3.1× Banco Santander SA's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | SAN | |
|---|---|---|
Market Cap | $598.96B | $191.46B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $14.37 |
52-Week Low | $164.36 | $8.40 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Banco Santander (SAN) trades at $13.31, down 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.41, beating expectations, but missed in prior quarters. Revenue for 2025 was $60.02B with a net income margin of 26.72%. Recent news highlights Santander's AI initiatives, acquisition of Webster Bank, and becoming Spain's most valuable company. Cash flow trends show operational challenges, with net cash flow negative in recent years.
Outlook is cautiously optimistic with a 64% analyst buy rating, targeting efficiency gains and AI-driven value. Risks include regulatory probes, declining cash flows, and high debt levels. The stock offers a dividend yield with the recent $0.15 payout, but investors should weigh operational improvements against financial volatility and macroeconomic pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
